Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
22 08 2022
Historique:
received: 07 01 2022
accepted: 22 07 2022
entrez: 22 8 2022
pubmed: 23 8 2022
medline: 25 8 2022
Statut: epublish

Résumé

In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm

Identifiants

pubmed: 35995780
doi: 10.1038/s41467-022-32263-7
pii: 10.1038/s41467-022-32263-7
pmc: PMC9395398
doi:

Substances chimiques

Antibodies, Viral 0
COVID-19 Vaccines 0
2019-nCoV Vaccine mRNA-1273 EPK39PL4R4
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4922

Investigateurs

Alessandra Amendola (A)
Francesco Baldini (F)
Rita Bellagamba (R)
Aurora Bettini (A)
Licia Bordi (L)
Marta Camici (M)
Rita Casetti (R)
Sarah Costantini (S)
Flavia Cristofanelli (F)
Claudia D'Alessio (C)
Veronica D'Aquila (V)
Alessia De Angelis (A)
Federico De Zottis (F)
Lydia de Pascale (L)
Massimo Francalancia (M)
Marisa Fusto (M)
Roberta Gagliardini (R)
Giulia Gramigna (G)
Germana Grassi (G)
Elisabetta Grilli (E)
Susanna Grisetti (S)
Denise Iafrate (D)
Daniele Lapa (D)
Patrizia Lorenzini (P)
Alessandra Marani (A)
Erminia Masone (E)
Stefano Marongiu (S)
Annalisa Mondi (A)
Stefania Notari (S)
Sandrine Ottou (S)
Jessica Paulicelli (J)
Luca Pellegrino (L)
Carmela Pinnetti (C)
Maria Maddalena Plazzi (MM)
Adriano Possi (A)
Alessandra Sacchi (A)
Eleonora Tartaglia (E)

Informations de copyright

© 2022. The Author(s).

Références

AIDS Care. 2022 May;34(5):663-669
pubmed: 33779425
Clin Infect Dis. 2022 Apr 9;74(7):1268-1270
pubmed: 34293114
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
Cancer Cell. 2022 Apr 11;40(4):338-339
pubmed: 35216675
Microorganisms. 2021 Jun 16;9(6):
pubmed: 34208751
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Lancet Reg Health Eur. 2022 Feb;13:100287
pubmed: 34961855
Clin Infect Dis. 2014 Apr;58(8):1130-9
pubmed: 24415637
J Clin Med. 2021 Oct 30;10(21):
pubmed: 34768631
Am J Med. 2019 Apr;132(4):437-446
pubmed: 30611828
Blood Adv. 2022 Jan 11;6(1):207-211
pubmed: 34844264
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Clin Infect Dis. 2022 Aug 24;75(1):e552-e563
pubmed: 35366316
Curr Opin Infect Dis. 2010 Feb;23(1):32-8
pubmed: 19949327
Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
NPJ Vaccines. 2022 Feb 28;7(1):28
pubmed: 35228535
Nat Commun. 2021 Oct 5;12(1):5839
pubmed: 34611163
Lancet HIV. 2021 Jan;8(1):e24-e32
pubmed: 33316211
Front Immunol. 2018 Mar 01;9:339
pubmed: 29545794
Clin Microbiol Infect. 2021 Dec;27(12):1851-1855
pubmed: 34438069
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
N Engl J Med. 2022 Jan 13;386(2):105-115
pubmed: 34942066
Sci Transl Med. 2021 Feb 3;13(579):
pubmed: 33536277
Lancet. 2022 Jan 15;399(10321):234-236
pubmed: 34942101
J Invest Dermatol. 2009 Feb;129(2):266-77
pubmed: 19148216
JAMA Oncol. 2022 Feb 1;8(2):300-301
pubmed: 34812840
Nat Med. 2021 Nov;27(11):2025-2031
pubmed: 34526698
Clin Infect Dis. 2011 Jan 15;52(2):219-27
pubmed: 21288848
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet HIV. 2021 Jun;8(6):e334-e341
pubmed: 33933189
AIDS. 2021 Nov 15;35(14):2399-2401
pubmed: 34261097
Annu Rev Med. 2011;62:141-55
pubmed: 21090961
N Engl J Med. 2021 Nov 4;385(19):1774-1785
pubmed: 34551225
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
HIV Med. 2022 May;23(5):558-563
pubmed: 34725907
AIDS. 2000 Sep 8;14(13):1921-33
pubmed: 10997396
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Lancet HIV. 2021 Aug;8(8):e474-e485
pubmed: 34153264
AIDS. 2000 Dec 1;14(17):2643-51
pubmed: 11125882
J Infect Dis. 2022 Apr 1;225(7):1141-1150
pubmed: 34888672
Clin Infect Dis. 2022 Aug 24;75(1):e916-e919
pubmed: 34864962
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695

Auteurs

Alessandra Vergori (A)

HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy. alessandra.vergori@inmi.it.

Alessandro Cozzi Lepri (A)

Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK.

Stefania Cicalini (S)

HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Giulia Matusali (G)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Veronica Bordoni (V)

Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.

Simone Lanini (S)

HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Silvia Meschi (S)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Roberta Iannazzo (R)

HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Valentina Mazzotta (V)

HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Francesca Colavita (F)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Ilaria Mastrorosa (I)

HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Eleonora Cimini (E)

Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.

Davide Mariotti (D)

Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.

Lydia De Pascale (L)

HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Alessandra Marani (A)

Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.

Paola Gallì (P)

Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.

AnnaRosa Garbuglia (A)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Concetta Castilletti (C)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Vincenzo Puro (V)

Risk Management Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.

Chiara Agrati (C)

Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.

Enrico Girardi (E)

Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.

Francesco Vaia (F)

Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.

Andrea Antinori (A)

HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH